Desglycinamide-(ARG8)-vasopressin in five trials with memory-disturbed patients

R. Hijman; J. Jolles; W.M.A. Verhoeven; J.M. Van Ree; A. Elderson

doi:10.1002/hup.470070103

Desglycinamide-(ARG8)-vasopressin in five trials with memory-disturbed patients

R. Hijman, J. Jolles, W.M.A. Verhoeven, J.M. Van Ree, A. Elderson

Research output: Contribution to journal › Article › Academic › peer-review

87 Downloads (Pure)

Abstract

A series of five consecutive clinical trials were performed in which the neuropeptide desglycinamide‐(Arg8)‐vasopressin (DGAVP) was administered to human subjects suffering from cognitive and memory complaints. The patients selected for the study were carefully screened with the aid of neuropsychological assessment procedures. The trials were conducted according to a structured design in which the variables ‘dose’, ‘route of administration’, ‘treatment schedule’, ‘diagnostic group’, and ‘severity of deficit’ were varied from trial to trial in order to find optimal conditions for the possible expression of a peptide effect. The results indicate a statistically significant effect of DGAVP on word list learning in patients with mild brain trauma, suggesting that learning performance and memory retrieval are improved after peptide treatment in these patients. Patients with more severe brain trauma did not respond to peptide treatment. Some DGAVP effects, e.g. increased speed of memory search, were observed in patients with age‐associated memory deficits.

Original language	English
Pages (from-to)	7-23
Number of pages	17
Journal	Human Psychopharmacology-Clinical and Experimental
Volume	7
DOIs	https://doi.org/10.1002/hup.470070103
Publication status	Published - 1 Jan 1992

Access to Document

10.1002/hup.470070103

Full TextFinal published version, 2.48 MB

Cite this

@article{36d2e796132b40d3bc50c35477194966,

title = "Desglycinamide-(ARG8)-vasopressin in five trials with memory-disturbed patients",

abstract = "A series of five consecutive clinical trials were performed in which the neuropeptide desglycinamide‐(Arg8)‐vasopressin (DGAVP) was administered to human subjects suffering from cognitive and memory complaints. The patients selected for the study were carefully screened with the aid of neuropsychological assessment procedures. The trials were conducted according to a structured design in which the variables {\textquoteleft}dose{\textquoteright}, {\textquoteleft}route of administration{\textquoteright}, {\textquoteleft}treatment schedule{\textquoteright}, {\textquoteleft}diagnostic group{\textquoteright}, and {\textquoteleft}severity of deficit{\textquoteright} were varied from trial to trial in order to find optimal conditions for the possible expression of a peptide effect. The results indicate a statistically significant effect of DGAVP on word list learning in patients with mild brain trauma, suggesting that learning performance and memory retrieval are improved after peptide treatment in these patients. Patients with more severe brain trauma did not respond to peptide treatment. Some DGAVP effects, e.g. increased speed of memory search, were observed in patients with age‐associated memory deficits.",

author = "R. Hijman and J. Jolles and W.M.A. Verhoeven and {Van Ree}, J.M. and A. Elderson",

year = "1992",

month = jan,

day = "1",

doi = "10.1002/hup.470070103",

language = "English",

volume = "7",

pages = "7--23",

journal = "Human Psychopharmacology-Clinical and Experimental",

issn = "0885-6222",

publisher = "Wiley",

}

TY - JOUR

T1 - Desglycinamide-(ARG8)-vasopressin in five trials with memory-disturbed patients

AU - Hijman, R.

AU - Jolles, J.

AU - Verhoeven, W.M.A.

AU - Van Ree, J.M.

AU - Elderson, A.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - A series of five consecutive clinical trials were performed in which the neuropeptide desglycinamide‐(Arg8)‐vasopressin (DGAVP) was administered to human subjects suffering from cognitive and memory complaints. The patients selected for the study were carefully screened with the aid of neuropsychological assessment procedures. The trials were conducted according to a structured design in which the variables ‘dose’, ‘route of administration’, ‘treatment schedule’, ‘diagnostic group’, and ‘severity of deficit’ were varied from trial to trial in order to find optimal conditions for the possible expression of a peptide effect. The results indicate a statistically significant effect of DGAVP on word list learning in patients with mild brain trauma, suggesting that learning performance and memory retrieval are improved after peptide treatment in these patients. Patients with more severe brain trauma did not respond to peptide treatment. Some DGAVP effects, e.g. increased speed of memory search, were observed in patients with age‐associated memory deficits.

AB - A series of five consecutive clinical trials were performed in which the neuropeptide desglycinamide‐(Arg8)‐vasopressin (DGAVP) was administered to human subjects suffering from cognitive and memory complaints. The patients selected for the study were carefully screened with the aid of neuropsychological assessment procedures. The trials were conducted according to a structured design in which the variables ‘dose’, ‘route of administration’, ‘treatment schedule’, ‘diagnostic group’, and ‘severity of deficit’ were varied from trial to trial in order to find optimal conditions for the possible expression of a peptide effect. The results indicate a statistically significant effect of DGAVP on word list learning in patients with mild brain trauma, suggesting that learning performance and memory retrieval are improved after peptide treatment in these patients. Patients with more severe brain trauma did not respond to peptide treatment. Some DGAVP effects, e.g. increased speed of memory search, were observed in patients with age‐associated memory deficits.

U2 - 10.1002/hup.470070103

DO - 10.1002/hup.470070103

M3 - Article

SN - 0885-6222

VL - 7

SP - 7

EP - 23

JO - Human Psychopharmacology-Clinical and Experimental

JF - Human Psychopharmacology-Clinical and Experimental

ER -